Evotec SE announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
↧